GridAI Technologies (GRDX) Other Non-Current Assets (2015 - 2025)
GridAI Technologies' (GRDX) quarterly Other Non-Current Assets came in at $83.2 million in Q3 2025, up 386377.74% YoY from N/an in Q3 2024, and little changed on a QoQ basis from $83.2 million in Q2 2025.
GridAI Technologies (GRDX) Other Non-Current Assets (2015 - 2025) Analysis & Trends
GridAI Technologies (GRDX) has 11 years of Other Non-Current Assets data on file, last reported at $83.2 million in Q3 2025.
- Quarterly Other Non-Current Assets rose 386377.74% year-over-year to $83.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $83.2 million (up 386377.74% YoY) and the FY2024 annual result came in at $83.2 million, up 739188.97% from the prior year.
- Other Non-Current Assets steadied at $83.2 million in Q3 2025, from $83.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $83.2 million in Q4 2024 to a low of $11250.0 in Q2 2023.
- A 5-year average of $17.8 million and a median of $34298.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets tumbled 99.44% — and 2024, when it surged 739188.97%.
- Tracing GRDX's Other Non-Current Assets over 5 years: stood at $44012.0 in 2021, then slumped by 51.12% to $21513.0 in 2022, then sank by 47.71% to $11250.0 in 2023, then surged by 739188.97% to $83.2 million in 2024, then changed by 0.0% to $83.2 million in 2025.
- The last three Other Non-Current Assets figures came in at $83.2 million (Q3 2025), $83.2 million (Q2 2025), and $83.2 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | GridAI Technologies | 5.82 Mn | 5.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 83.17 Mn |
| Jun 30, 2025 | 83.17 Mn |
| Mar 31, 2025 | 83.17 Mn |
| Dec 31, 2024 | 83.17 Mn |
| Sep 30, 2024 | 21,520.00 |
| Jun 30, 2024 | 21,516.00 |
| Mar 31, 2024 | 11,250.00 |
| Dec 31, 2023 | 11,250.00 |
| Sep 30, 2023 | 11,250.00 |
| Jun 30, 2023 | 11,250.00 |
| Mar 31, 2023 | 18,149.00 |
| Dec 31, 2022 | 21,513.00 |
| Sep 30, 2022 | 34,298.00 |
| Jun 30, 2022 | 34,326.00 |
| Mar 31, 2022 | 34,397.00 |
| Dec 31, 2021 | 44,012.00 |
| Sep 30, 2021 | 44,034.00 |
| Jun 30, 2021 | 5.07 Mn |
| Mar 31, 2021 | 29,242.00 |
| Dec 31, 2020 | 27,920.00 |